ABVC BioPharma (Nasdaq:ABVC) - Hisse Senedi Fiyatı, Haberler ve Analizler

ABVC Stoklara Genel Bakış

ABVC temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	3/6
Temettüler	0/6

Risk Analizi

1 yıldan az nakit akışı var

Geliri 1 milyon ABD dolarından az ( $510K )

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Anlamlı bir piyasa değeri yok ( $7M )

+ 2 daha fazla risk

ABVC BioPharma, Inc. Rakipler

Mainz Biomed

NasdaqCM:MYNZ

US$5.3m

Ensysce Biosciences

NasdaqCM:ENSC

US$11.6m

Soligenix

NasdaqCM:SNGX

US$8.4m

Eagle Pharmaceuticals

OTCPK:EGRX

US$11.7m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti ABVC BioPharma
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.55
52 Haftanın En Yüksek Seviyesi	US$2.45
52 Haftanın En Düşük Seviyesi	US$0.41
Beta	0.82
11 Aylık Değişim	-3.72%
3 Aylık Değişim	-23.26%
1 Yıllık Değişim	-72.83%
33 Yıllık Değişim	-98.29%
5 Yıllık Değişim	-99.17%
Halka arzdan bu yana değişim	-97.61%

Son Haberler & Güncellemeler

Recent updates

ABVC BioPharma (NASDAQ:ABVC) Is Carrying A Fair Bit Of Debt

Mar 13

Australian ethics committee approves ABVC's phase 2 study plan for its eye-gel substitute

Oct 05

ABVC Biopharma rises on clinical update from Phase 2 trial of ADHD drug

Sep 23

ABVC BioPharma (NASDAQ:ABVC) Has Debt But No Earnings; Should You Worry?

Aug 18

ABVC BioPharma GAAP EPS of -$0.06 beats by $0.07, revenue of $0.31M beats by $0.3M

Aug 17

ABVC Biopharma rises 18% on acceleration of ADHD drug Phase 2 trial

Jul 13

Thai ethics committee approves ABVC's phase 2 study protocol for its eye-gel substitute

Jun 30

Hissedar Getirileri

	ABVC	US Biotechs	US Pazar
7D	9.8%	2.4%	2.2%
1Y	-72.8%	16.2%	31.7%

Getiri vs. Endüstri: ABVC geçen yıl % 16.2 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: ABVC geçen yıl % 31.7 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is ABVC's price volatile compared to industry and market?
ABVC volatility
ABVC Average Weekly Movement	12.6%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: ABVC hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: ABVC 'nin haftalık oynaklığı ( 13% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	18	Uttam Patil	www.abvcpharma.com

Klinik aşamada bir biyofarmasötik şirketi olan ABVC BioPharma, Inc. Amerika Birleşik Devletleri'nde karşılanmamış tıbbi ihtiyaçları karşılamak için ilaçlar ve tıbbi cihazlar geliştirmektedir. Şirket, Faz II klinik çalışmalarında üçlü negatif meme kanseri için bir kombinasyon tedavisi olan ABV-1501'i geliştirmektedir; ABV-1504, majör depresif bozukluklar için Faz II klinik çalışmalarını tamamlamıştır; ABV-1505, yetişkin dikkat eksikliği hiperaktivite bozukluğu için Faz II klinik çalışmalarındadır; Metastatik pankreas kanseri tedavisi için Faz II klinik çalışmalarında olan ABV-1703; miyelodisplastik sendromları tedavi etmek için Faz II klinik çalışmalarında olan ABV-1702; ve kanser hastalarında depresyon tedavisi için Faz I/II klinik çalışmalarında olan ABV-1601. Ayrıca retina dekolmanı veya vitreus kanaması tedavisi için Faz II klinik çalışmalarında olan ABV-1701 Vitargus ve küçük hücreli dışı akciğer kanseri tedavisi için Faz I/II klinik çalışmalarında olan ABV-1519'u geliştirmektedir.

ABVC BioPharma, Inc. Temel Bilgiler Özeti

ABVC BioPharma'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ABVC temel i̇stati̇sti̇kler
Piyasa değeri	US$6.59m
Kazançlar(TTM)	-US$8.24m
Gelir(TTM)	US$509.79k

12.9x

P/S Oranı

-0.8x

F/K Oranı

ABVC aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ABVC gelir tablosu (TTM)
Gelir	US$509.79k
Gelir Maliyeti	US$139.97k
Brüt Kâr	US$369.82k
Diğer Giderler	US$8.61m
Kazançlar	-US$8.24m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.69
Brüt Marj	72.54%
Net Kâr Marjı	-1,616.97%
Borç/Özkaynak Oranı	22.8%

ABVC uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

ABVC Stoklara Genel Bakış

Risk Analizi

ABVC BioPharma, Inc. Rakipler

NasdaqCM:MYNZ

US$5.3m

NasdaqCM:ENSC

US$11.6m

NasdaqCM:SNGX

US$8.4m

OTCPK:EGRX

US$11.7m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

ABVC BioPharma Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirements Set Forth in Nasdaq Listing Rule 5550(a)(2)

ABVC BioPharma, Inc. announced delayed 10-Q filing

ABVC BioPharma, Inc., Annual General Meeting, Apr 16, 2024

ABVC BioPharma, Inc., Annual General Meeting, Apr 17, 2024

ABVC BioPharma, Inc. announced that it has received $0.833333 million in funding from The Lind Partners, LLC

ABVC BioPharma, Inc., Annual General Meeting, Jan 16, 2024

Recent updates

ABVC BioPharma Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirements Set Forth in Nasdaq Listing Rule 5550(a)(2)

ABVC BioPharma, Inc. announced delayed 10-Q filing

ABVC BioPharma, Inc., Annual General Meeting, Apr 16, 2024

ABVC BioPharma, Inc., Annual General Meeting, Apr 17, 2024

ABVC BioPharma, Inc. announced that it has received $0.833333 million in funding from The Lind Partners, LLC

ABVC BioPharma, Inc., Annual General Meeting, Jan 16, 2024

ABVC BioPharma, Inc. Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study

ABVC BioPharma, Inc. announced delayed 10-Q filing

Abvc Biopharma, Inc. Announces Completion of Subject Recruitment for Interim Analysis on Adhd Phase Iib Clinical Study

ABVC BioPharma Regains Compliance with Nasdaq's Minimum Bid Price Requirement

ABVC BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $1.75 million.

ABVC BioPharma, Inc. announced that it expects to receive $1.75 million in funding

Nasdaq Grants ABVC Biopharma an Extension to Comply with Listing Rule 5550(b)(1)

ABVC Biopharma, Inc. Appoints Dr. Uttam Yashwant Patil as Chief Executive Officer

ABVC BioPharma Receives Deficiency Letter from Nasdaq Due to Non-Compliance with the Minimum Stockholders' Equity Requirement

ABVC BioPharma, Inc. Announces Vitargus®? Phase II Study Receives Ethical Approval At Sydney Eye Hospital in Australia

First quarter 2023 earnings released: US$0.055 loss per share (vs US$0.20 loss in 1Q 2022)

ABVC BioPharma (NASDAQ:ABVC) Is Carrying A Fair Bit Of Debt

ABVC BioPharma Receives an Additional 180 Days, Until August 14, 2023, to Comply with Rule 5550(a)(2)

Abvc Biopharma Abv-1505 Adhd Phase Iia Results Presented At 2023 Apsard Conference

FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer

ABVC BioPharma, Inc. Receives Thai FDA Approval for Phase II Vitargus Study Protocol

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder

ABVC BioPharma, Inc. Announces That Cedars-Sinai Medical Center Institutional Review Board (IRB) Approves Institution Joining the Phase I Study of ABV-1601

ABVC BioPharma, Inc. Announces Vitargus(R) Phase II Study Plan Approved by Hrec in Australia

Australian ethics committee approves ABVC's phase 2 study plan for its eye-gel substitute

Abvc Biopharma, Inc. Provides Adhd Phase Ii Part 2 Clinical Study Update and Announces Ucsf Institutional Review Board Approval

ABVC Biopharma rises on clinical update from Phase 2 trial of ADHD drug

ABVC BioPharma Receives Non-Compliance Letter from Nasdaq

ABVC BioPharma, Inc. Provides Vitargus Update

ABVC BioPharma (NASDAQ:ABVC) Has Debt But No Earnings; Should You Worry?

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

ABVC BioPharma GAAP EPS of -$0.06 beats by $0.07, revenue of $0.31M beats by $0.3M

ABVC BioPharma, Inc. Provides Vitargus Update

ABVC BioPharma, Inc. Announces Board Changes

ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update

ABVC Biopharma rises 18% on acceleration of ADHD drug Phase 2 trial

ABVC BioPharma, Inc. Announces the Vitargus® Phase II Clinical Study Protocol Approval by the Central Research Ethics Committee (CREC) of the National Research Council of Thailand

Thai ethics committee approves ABVC's phase 2 study protocol for its eye-gel substitute

ABVC BioPharma, Inc. Submitts Vitargus(R) Phase II Study Plan to Australia HREC

Abvc Biopharma, Inc. Appoints Ms. Hsin-Hui Miao to its Board

ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study

ABVC BioPharma, Inc. Announces Board Elections

First quarter 2022 earnings: EPS and revenues miss analyst expectations

ABVC BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $4.22 million.

ABVC BioPharma, Inc. Announces ADHD Phase II Part 2 Clinical Study First Subject

ABVC Biopharma Announces Streamlined Vitargus® Manufacturing Process

Insufficient new directors

ABVC BioPharma, Inc. Announces Vitargus Phase II Clinical Study Investigator Meeting

Is ABVC BioPharma (NASDAQ:ABVC) Using Too Much Debt?

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study

ABVC BioPharma, Inc. Selects Additional Vitargus Phase II Study Sites

Is ABVC BioPharma (NASDAQ:ABVC) A Risky Investment?

High number of new directors

Third quarter 2021 earnings released: US$0.067 loss per share (vs US$0.095 loss in 3Q 2020)

High number of new directors

High number of new directors